drugset / Trial / NCT01830465
VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study was to evaluate the efficacy and safety of the combination of Velcade and Rituximab in patients with relapsed Non Hodgkin's Follicular Lymphoma.
Timeline
- Start
- 2006-08
- Primary completion
- 2008-08
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |